



University of Dundee

CYLD mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome

Parren, Lizelotte J. M. T.; Baron, Jens M.; Joussem, Sylvia; Marquardt, Yvonne; Hanneken, Sandra; van Steensel, Maurice A. M.; Steijlen, Peter M.; van Geel, Michel; Frank, Jorge

Published in:

Journal of the European Academy of Dermatology and Venereology

DOI:

[10.1111/jdv.14889](https://doi.org/10.1111/jdv.14889)

Publication date:

2018

Document Version

Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Parren, L. J. M. T., Baron, J. M., Joussem, S., Marquardt, Y., Hanneken, S., van Steensel, M. A. M., ... Frank, J. (2018). CYLD mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome. *Journal of the European Academy of Dermatology and Venereology*. <https://doi.org/10.1111/jdv.14889>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Article type: Letter to Editor

CYLD mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome

Lizelotte J.M.T. Parren^{1,2,3}, Jens M. Baron⁴, Sylvia Joussem⁵, Yvonne Marquardt⁴, Sandra Hanneken⁶, Maurice A.M. van Steensel^{7,8}, Peter M. Steijlen^{2,3}, Michel van Geel^{2,3,9}, and Jorge Frank¹⁰

¹Department of Dermatology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands;

²Department of Dermatology and ³GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center (MUMC), The Netherlands;

⁴Department of Dermatology and Allergology, RWTH Aachen University, Aachen, Germany;

⁵Institute of Physiology, RWTH Aachen University, Aachen, Germany

⁶Private Practice Empoderm, Graf-Adolf-Strasse 88; 40210 Düsseldorf, Germany;

⁷Institute of Medical Biology, Immunos, Singapore

⁸Division of Cancer Science, College of Medicine, Dentistry and Nursing; Department of Biological Chemistry and Drug Discover, College of Life Sciences, University of Dundee, Dundee, UK

⁹Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands

¹⁰Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany

Subject category: Letter to the editor

Running title: *CYLD* splice site mutations

This is the peer reviewed version of the following article: 'CYLD mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome', *Journal of the European Academy of Dermatology and Venerology*, which has been published in final form at <http://dx.doi.org/10.1111/jdv.14889>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

This article is protected by copyright. All rights reserved.

Address for correspondence:

Univ.-Prof. Dr. med. Jorge Frank, M.D.

Department of Dermatology, Venereology and Allergology

University Medical Center Göttingen

Robert-Koch-Str. 40

37075 Göttingen; Germany

Phone +49-551-3966402

Fax +49-551-3966841

e-mail jorge.frank@med.uni-goettingen.de

Statement of funding sources: None

Conflict of interest: None

ABBREVIATIONS

BSS Brooke-Spiegler syndrome

NHEK Normal human epidermal keratinocytes

PBMC Peripheral blood mononuclear cells

PTC Premature termination codon

qRT-PCR Quantitative reverse transcriptase polymerase chain reaction

RT-PCR Reverse transcriptase polymerase chain reaction

KEY WORDS

Brooke-Spiegler syndrome; CYLD; familial cylindromatosis; mRNA decay; splice site mutation

EDITOR,

Brooke-Spiegler syndrome (BSS; OMIM 605041), also known as familial cylindromatosis (OMIM 132700), is an autosomal dominant tumour predisposition disorder characterised by the occurrence of cylindromas, trichoepitheliomas, and spiradenomas.¹ BSS is caused by heterogenous mutations in the *CYLD* gene. To date, different *CYLD* mutations have been reported, most of them resulting in a premature termination codon (PTC).² Among these, thirteen splice site mutations have been described.^{2,3} However, it remains largely elusive how such mutations affect splicing.²

Here, we studied three unrelated Caucasian patients with BSS who were initially diagnosed both clinically and histopathologically (Table 1). To unequivocally confirm the diagnosis, we performed mutation analysis of the *CYLD* gene which revealed three splice site mutations. In order to select appropriate tissues for RNA studies, we assessed the expression of *CYLD* in normal human epidermal keratinocytes (NHEK), leukocytes and peripheral blood mononuclear cells (PBMC) by quantitative reverse transcriptase (qRT)-PCR. In all patients, residual mRNA levels were measured in RNA specimens derived from whole blood.

We detected three *CYLD* splice site mutations, designated c.2108+1G>A (Fig. 1a), c.2242-2A>G (Fig. 1b), and c.2109-2A>C (Fig. 1c). These mutations were associated with distinct phenotypes, respectively (Table 1). Interestingly, the first patient carried a novel mutation

that was not detectable in either parent. Paternity was confirmed by haplotype analysis (data not shown). To the best of our knowledge, c.2108+1G>A represents the first *de novo* mutation reported in BSS. All mutations were shown by restriction enzyme digestion to be absent from 100 unrelated, unaffected Caucasian control individuals (data not shown).

Comparison of mRNA expression by RT-PCR revealed that *CYLD* is expressed at almost equal levels in NHEK, leukocytes and PBMC (data not shown). In the patients carrying mutations c.2108+1G>A and c.2242-2A>G, RT-PCR on RNA derived from PBMCs revealed the wild-type product containing 430 base pairs (bp) and a smaller additional band of 363 and 321 bp, respectively. Automated DNA sequencing showed that the smaller bands represented fragments excluding exons 15 and 17, respectively (data not shown). Both exon skipping events lead to putative out-of-frame translation and generation of a PTC. For mutation c.2108+1G>A the PTC is located 30 codons downstream of the mutation site (p.Pro682Gln31fs*) and for c.2242-2A>G, 47 codons downstream of the mutation (p.Ala748Leufs48*). Of note, we did not detect an aberrant splicing pattern for c.2109-2A>C. This finding suggested that the transcript of the mutated allele is subject to nonsense-mediated mRNA decay.

To study the role of nonsense-mediated mRNA decay in the three splice site mutations detected here, we measured *CYLD* mRNA expression in peripheral blood leukocytes by qRT-PCR. Whereas mutations c.2108+1G>A and c.2242-2A>G do not result in a significant decrease of mRNA levels, mutation c.2109-2A>C is associated with approximately 60% mRNA decay when compared to a control (Fig. 1d).

The patient harbouring mutation c.2109-2A>C presented with cylindromas exclusively. This mutation has been previously reported in a family with trichoepitheliomas only, which suggests that the residual amounts of *CYLD* mRNA seem to be unrelated to the distinct phenotypes of individuals with this *CYLD* splice site defect.⁴ To date, fifteen splice site

Accepted Article

mutations have been reported to underlie different phenotypes, comprising Brooke-Spiegler syndrome (30%), familial cylindromatosis (35%), and multiple familial trichoepithelioma (35%).^{2,3} These previous reports and our own data confirm the previous notion that there is no apparent genotype-phenotype correlation in diseases caused by *CYLD* mutations.² Possibly, as of yet unknown environmental factors, modifier genes or epigenetic events could contribute to the different phenotypes observed.^{5,6}

REFERENCES

1. Ansell H. History of a remarkable case of tumours developed on the head and face; accompanied with a similar disease in the abdomen. *Med Chir Trans* 1842;**25**:227-46.
2. Nagy N, Farkas K, Kemény K, Széll M. Phenotype-genotype correlations for clinical variants caused by *CYLD* mutations. *Eur J Med Genet* 2015;**58**:271-8.
3. Fujii A, Matsuyama K, Mizutani Y, Kanoh H, Nakona H, Sishima M. Multiple familial trichoepithelioma with a novel mutation of the *CYLD* gene. *J Dermatol*. 2017; epub ahead of print.
4. Duparc A, Lasek-Duriez A, Wiart T, Duban-Bedu B, Gosset P, Modiano P. Multiple familial trichoepithelioma: a new *CYLD* gene mutation. *Ann Dermatol Venereol*. 2013;**140**:274-7.
5. Massoumi R. Ubiquitin chain cleavage: CYLD at work. *Trends Biochem. Sci* 2010;**35**:392-9.
6. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. *Mol. Cell* 2010;**39**:493-506.

LEGENDS TO TABLE AND FIGURES

Table 1 *CYLD* splice site mutations in this study, associated phenotypes, and the structural and functional consequences of these mutations.

Figure 1 a-c) Splice site mutations detected in this study, designated c.2108+1G>A; c.2242-2A>G; and c.2109-2A>C. d) Quantitative real-time PCR indicates that mutations C.2108+1G>A and C.2242-2A>G are not associated with relevant mRNA decay. By contrast, mutation C.2109-2A>C leads to substantial mRNA decay.

Mutation	c.2108+1G>A	c.2242-2A>G	c.2109-2A>C
Phenotype	Cylindromas and trichoepitheliomas	Cylindromas and trichoepitheliomas	Cylindromas
Novel or recurrent mutation	Novel	Novel	Recurrent
Consequence of splicing defect	Exon skipping	Exon skipping	Nonsense-mediated mRNA decay
Levels of mRNA	Normal	Normal	40% of normal

Table 1 *CYLD* splice site mutations in this study, associated phenotypes as well as the structural and functional consequences of these mutations.



